Bayer (FRA:BAYN) Given a €70.00 Price Target at Deutsche Bank

Deutsche Bank set a €70.00 ($81.40) price target on Bayer (FRA:BAYN) in a research note released on Friday, Borsen Zeitung reports. The brokerage currently has a neutral rating on the healthcare company’s stock.

A number of other equities analysts also recently weighed in on BAYN. Baader Bank set a €123.00 ($143.02) price target on shares of Bayer and gave the stock a buy rating in a report on Wednesday, August 7th. UBS Group set a €110.00 ($127.91) price target on shares of Bayer and gave the stock a buy rating in a report on Wednesday, September 25th. DZ Bank reissued a neutral rating on shares of Bayer in a report on Monday, October 21st. Goldman Sachs Group set a €77.00 ($89.53) price target on shares of Bayer and gave the stock a buy rating in a report on Tuesday, October 22nd. Finally, Kepler Capital Markets set a €70.00 ($81.40) price target on shares of Bayer and gave the stock a neutral rating in a report on Thursday, June 27th. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating and eleven have given a buy rating to the company’s stock. The company presently has a consensus rating of Hold and a consensus price target of €79.90 ($92.91).

Shares of FRA:BAYN opened at €65.93 ($76.66) on Friday. The company’s 50-day moving average is €65.57 and its 200 day moving average is €60.81. Bayer has a fifty-two week low of €91.58 ($106.49) and a fifty-two week high of €123.82 ($143.98).

Bayer Company Profile

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

See Also: What is the NASDAQ?

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.